NanoVibronix Announces Positive Results from Independent Product Trial of UroShield for Patients with a Spinal Cord InjuryBusiness Wire • 03/14/23
NanoVibronix Announces Closing of $2.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesBusiness Wire • 12/01/22
NanoVibronix Announces $2.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesBusiness Wire • 11/29/22
NanoVibronix UroShield Approved for Sale through NHS Internal Supply Chain ContractBusiness Wire • 09/23/22
NanoVibronix Announces Distribution of Series F Preferred Stock to Holders of its Common StockBusiness Wire • 09/14/22
NanoVibronix Announces Receipt of Nasdaq Listing Determination; Company to Request HearingBusiness Wire • 09/02/22
NanoVibronix Strengthening Supply Chain Increasing Efficiency and ScalabilityBusiness Wire • 06/29/22